Assuntos
Aprovação de Drogas/organização & administração , Desenvolvimento de Medicamentos , Leiomioma/tratamento farmacológico , Saúde da Mulher , Tamanho Corporal , Doença Hepática Induzida por Substâncias e Drogas , Contraceptivos Hormonais/farmacocinética , Suplementos Nutricionais , Interações Medicamentosas , Feminino , Hormônio Liberador de Gonadotropina/análogos & derivados , Hormônio Liberador de Gonadotropina/antagonistas & inibidores , Hormônio Liberador de Gonadotropina/farmacocinética , Antagonistas de Hormônios/efeitos adversos , Antagonistas de Hormônios/farmacocinética , Antagonistas de Hormônios/farmacologia , Humanos , Farmacologia Clínica , Congêneres da Progesterona/efeitos adversos , Congêneres da Progesterona/farmacocinética , Congêneres da Progesterona/farmacologia , Fatores RaciaisRESUMO
In this study, sustained-release of GnRH antagonist peptide LXT-101 was realized through oil formulation, and their releasing characteristics in vitro and in vivo were investigated. In this formulation, the static interaction between cationic charged peptide LXT-101 and the negative charged phospholipid led to the formation of the phospholipid-peptide complex, by which LXT-101 was completely dissolved in oils. This formulation was prepared by mixing an aqueous solution of LXT-101 and empty SUV (small unilamellar liposomes) containing EPC (phosphatidylcholine) and DPPG (1, 2-dipalmitog-sn-glycero-3- phosphoglycerol) at an appropriate ratio, the mixture was subsequently lyophilized, and the resultant was dissolved in the oil to form a clear oily solution containing solubilized peptide LXT-101. With atomic force microscopy combined with Langmuir-Blodgett technology, the morphology of the particles in the oily solution were examined to be oval-shaped and the mean particle size was 150 nm in diameter. In pure water at 37°C, about 70~90 % of LXT-101 was released slowly from the oily formulation over 7 days. An effective sustained suppression of testosterone in beagle dogs could be achieved over a period of seven days with this LXT-101 oily formulation, by i.m. at a dose of 0.2 mg/kg (2 mg/ml). This formulation dramatically improved the bioactivity of LXT-101 compared to its aqueous solution. It was also found that when the concentration of peptide LXT-101 was up to or over 10 mg/ml in aqueous solution, there was no significant difference between the oily formulation and aqueous solution. This fact meant that LXT-101 itself could conduct sustained release in vivo by self-assembly of nanofibers.
Assuntos
Antagonistas de Hormônios/administração & dosagem , Oligopeptídeos/administração & dosagem , Animais , Preparações de Ação Retardada/administração & dosagem , Preparações de Ação Retardada/química , Preparações de Ação Retardada/farmacocinética , Cães , Hormônio Liberador de Gonadotropina/antagonistas & inibidores , Antagonistas de Hormônios/sangue , Antagonistas de Hormônios/química , Antagonistas de Hormônios/farmacocinética , Injeções , Lipossomos , Masculino , Ácido Oleico/química , Oligopeptídeos/sangue , Oligopeptídeos/química , Oligopeptídeos/farmacocinética , Fosfatidilcolinas/química , Fosfatidilgliceróis/química , Óleo de Soja/química , Testosterona/sangue , Triglicerídeos/química , Água/químicaRESUMO
CONTEXT: Assisted reproductive technology (ART) cycle cancelation rates are increased among overweight and obese women; however, the reasons for this are not completely clear. Premature luteinization due to inadequate endogenous gonadotropin suppression is a possibility for this higher risk of cancellation. OBJECTIVE: The objective of the study was to investigate the impact of female obesity on the pharmacokinetics of cetrorelix (GnRH antagonist). DESIGN: This was an interventional study. SETTING: The study was conducted at a university clinical and translational research center. PARTICIPANTS: Regularly menstruating obese (n = 10) and normal-weight (n = 10) women participated in the study. INTERVENTIONS: A frequent blood sampling study was performed after a GnRH antagonist was administered, followed by recombinant LH. MAIN OUTCOMES MEASURED: Pharmacokinetics of cetrorelix in obese vs normal weight women were measured. RESULTS: Five of the obese women (50%) and none of the normal-weight women had a rebound of LH (defined as >50% increase in LH level from nadir) over the 14-hour postdose observation period. The obese group had a significantly decreased distributional half-life of cetrorelix compared with the normal-weight group (8.1 ± 1.6 vs 12.7 ± 6.2 hours, P = .02). The obese group exhibited increased clearance of cetrorelix compared with the normal-weight group (25.8 ± 6.8 vs 20.1 ± 8.3 L/h, P = .058). CONCLUSIONS: The altered pharmacokinetics of cetrorelix in obese women may lead to premature ovulation during ART, and this could be one of the mechanisms that results in increased cycle cancelation in this group of women. In accordance with the higher gonadotropin requirements for obese women undergoing ART, weight-based dosing of GnRH antagonists may be required.
Assuntos
Hormônio Liberador de Gonadotropina/análogos & derivados , Antagonistas de Hormônios/farmacocinética , Hipotálamo/efeitos dos fármacos , Obesidade/metabolismo , Adulto , Feminino , Hormônio Foliculoestimulante/sangue , Hormônio Liberador de Gonadotropina/sangue , Hormônio Liberador de Gonadotropina/farmacocinética , Antagonistas de Hormônios/sangue , Humanos , Hormônio Luteinizante/sangue , Obesidade/sangue , Indução da Ovulação/métodosRESUMO
LXT-101, a cationic peptide is a novel antagonist of gonadotropin-releasing hormone (GnRH) for prostate cancer treatment. However, effective delivery of peptide drugs into the body by the oral route remains a major challenge due to their origin properties with high molecular weights, strong polarity and low stability in the gastrointestinal (GI) tract. In this study, we have developed a novel oral delivery of oil-based formulation in which therapeutic peptide LXT-101 are solubilized in oils and with this solution as oil phase, an optimum formulation of self-microemulsifying drug delivery system (SMEDDS) was developed. The peptide stability with the SMEDDS formulation in artificial gastric and intestinal fluid was tested in vitro. On the other hand, the testosterone level and plasma concentration of LXT-101 in rats after oral administration of the SMEDDS formulation were investigated in vivo. The data in vitro indicated that LXT-101 in the SMEDDS formulation was stable over 8 h in artificial gastric and intestinal fluid. LXT-101 can be absorbed in vivo and suppression of testosterone maintained in castration level within 12 h can be achieved effectively after SMEDDS formulation administered orally at a dose of 3.5 mg/kg. The approach can provide a potential way for delivery peptides by oral.
Assuntos
Hormônio Liberador de Gonadotropina/antagonistas & inibidores , Antagonistas de Hormônios/administração & dosagem , Oligopeptídeos/administração & dosagem , Administração Oral , Animais , Óleo de Rícino/química , Castração , Antagonistas de Hormônios/química , Antagonistas de Hormônios/farmacocinética , Masculino , Oligopeptídeos/química , Oligopeptídeos/farmacocinética , Pancreatina/química , Pepsina A/química , Fosfatidilcolinas/química , Fosfatidilgliceróis/química , Propilenoglicol/química , Neoplasias da Próstata/tratamento farmacológico , Ratos , Ratos Wistar , Testosterona/sangueRESUMO
AG-045572 (CMPD1, 1 a) is a nonpeptidic gonadotropin-releasing hormone (GnRH) antagonist that has been investigated for the treatment of sex hormone-related diseases. In the context of systematic studies on sila-substituted drugs, the silicon analogue disila-AG-045572 (1 b) and its derivative 2 were prepared in multi-step syntheses and characterized by elemental analyses (C, H, N), NMR spectroscopic studies (1H, 13C, 29Si), and single-crystal X-ray diffraction. The pharmacological properties of compounds 1 a, 1 b, and 2 were compared in terms of their in vitro potency at cloned human and rat GnRH receptors. Compounds 1 a and 2 were also examined in regard to their pharmacokinetics and in vivo efficacy in both castrated rat (luteinizing hormone (LH) suppression) and intact rat (testosterone suppression) models. The efficacy and pharmacokinetic profiles of 1 a and its silicon-containing analogue 2 appear similar, indicating that replacement of the 5,6,7,8-tetrahydronaphthalene ring system by the 1,3-disilaindane skeleton led to retention of efficacy. Therefore, the silicon compound 2 represents a novel drug prototype for the design of potent, orally available GnRH antagonists suitable for once-daily dosing.
Assuntos
Furanos/química , Hormônio Liberador de Gonadotropina/antagonistas & inibidores , Antagonistas de Hormônios/química , Antagonistas de Hormônios/farmacologia , Tetra-Hidronaftalenos/química , Animais , Cristalografia por Raios X , Avaliação Pré-Clínica de Medicamentos , Furanos/farmacologia , Antagonistas de Hormônios/farmacocinética , Humanos , Hormônio Luteinizante/antagonistas & inibidores , Espectroscopia de Ressonância Magnética , Masculino , Estrutura Molecular , Orquiectomia , Ratos Wistar , Receptores LHRH/genética , Silício/química , Relação Estrutura-Atividade , Tetra-Hidronaftalenos/farmacologiaRESUMO
Preterm birth, the leading cause of neonatal morbidity and mortality, is estimated at incidence of 12.7% of all births, which has not decreased over the last four decades despite intensive antenatal care programs aimed at high-risk groups, the widespread use of tocolytics, and a series of other preventive and therapeutic interventions. Oxytocin antagonists, namely atosiban, represent an appealing choice that seems to be effective with apparently fewer side effects than the traditional tocolytics. This article reviews the available literature on the pharmacokinetics, mode of administration, and clinical utility of oxytocin antagonists for acute and maintenance tocolysis with special emphasis on its safety profile.
Assuntos
Antagonistas de Hormônios/uso terapêutico , Ocitocina/antagonistas & inibidores , Nascimento Prematuro/prevenção & controle , Tocolíticos/uso terapêutico , Vasotocina/análogos & derivados , Feminino , Antagonistas de Hormônios/administração & dosagem , Antagonistas de Hormônios/farmacocinética , Humanos , Indóis/uso terapêutico , Nifedipino/uso terapêutico , Oligopeptídeos/uso terapêutico , Pirrolidinas/uso terapêutico , Simpatomiméticos/uso terapêutico , Tocolíticos/administração & dosagem , Tocolíticos/farmacocinética , Vasotocina/administração & dosagem , Vasotocina/farmacocinética , Vasotocina/uso terapêuticoRESUMO
Central administration of oxytocin (OT) antagonists inhibits maternal and sexual behavior in non-primates, providing the strongest experimental evidence that endogenous OT facilitates these behaviors. While there have been a few reports that ICV administration of OT increases social behaviors in monkeys, no studies to date have assessed the effects of OT antagonists. Therefore, we studied in rhesus monkeys whether L368,899, a non-peptide antagonist produced by Merck that selectively blocks the human uterine OT receptor, penetrates the CNS after peripheral administration and alters female maternal and sexual behavior. In two studies in four male monkeys, L368,899 was injected iv (1 mg/kg) after which (1) CSF samples were collected at intervals over 4 h and (2) brains were collected at 60 min. Assay of samples confirmed that iv-administered L368,899 entered CSF and accumulated in the hypothalamus, septum, orbitofrontal cortex, amygdala and hippocampus, but not other areas. An adult female monkey was tested for interest in either an infant or sexual behavior, receiving a different iv treatment prior to each test (1 or 3 mg/kg of L368,899 or saline). OT antagonist treatment reduced or eliminated interest in the infant and sexual behavior. These results, although preliminary, are the first to directly implicate endogenous OT in activation of primate maternal interest and sexual behavior. While it remains to be empirically demonstrated that peripherally administered L368,899 blocks central OT receptors, our behavioral findings suggest that this non-peptide antagonist may facilitate testing OT involvement in a variety of social and other behaviors in primates.
Assuntos
Canfanos/farmacocinética , Antagonistas de Hormônios/farmacocinética , Sistema Límbico/metabolismo , Comportamento Materno/efeitos dos fármacos , Piperazinas/farmacocinética , Comportamento Sexual Animal/efeitos dos fármacos , Tonsila do Cerebelo/metabolismo , Animais , Barreira Hematoencefálica/metabolismo , Canfanos/sangue , Canfanos/farmacologia , Feminino , Lobo Frontal/metabolismo , Hipocampo/metabolismo , Antagonistas de Hormônios/sangue , Antagonistas de Hormônios/farmacologia , Hipotálamo/metabolismo , Macaca mulatta , Masculino , Ocitocina/antagonistas & inibidores , Piperazinas/sangue , Piperazinas/farmacologia , Septo do Cérebro/metabolismoRESUMO
OBJECTIVE: To assess the dose-proportionality and pharmacodynamic properties of multiple doses of ganirelix (Antagon/Orgalutran; NV Organon, Oss, the Netherlands). DESIGN: Randomized, parallel, pharmacokinetic, and pharmacodynamic study. SETTING: Phase I clinical research unit. PATIENT(S): Three groups of 15 healthy female volunteers of reproductive age. INTERVENTION(S): Subcutaneous injections of 0.125 mg, 0.25 mg, or 0.50 mg of ganirelix were given once daily for 7 days. Blood samples were taken to assess serum ganirelix, LH, FSH, and E2 concentrations. MAIN OUTCOME MEASURE(S): Pharmacokinetic parameters and hormone suppression. RESULT(S): Steady-state levels were reached between days 2 and 3. Peak concentrations, which occurred approximately 1 hour after dosing, increased in a dose-proportional manner and averaged 5.2 ng/mL, 11.2 ng/mL, and 22.2 ng/mL for the 0.125-mg, 0.25-mg, and 0.50-mg doses, respectively. Corresponding mean values for the area under the curve over one dosing interval (24 hours) were 33 ng x h/mL, 77.1 ng x h/mL, and 137.8 ng x h/mL, respectively. After the last 0.25-mg dose of ganirelix, serum LH, FSH, and E2 concentrations were maximally decreased (by 74%, 32%, and 25% at 4 hours, 16 hours, and 16 hours after injection, respectively). Serum hormone levels returned to pretreatment values within 2 days after the last injection. CONCLUSION(S): The pharmacokinetics of ganirelix were dose-proportional within the dose range studied. Multiple injections resulted in immediate suppression of gonadotropins, which was rapidly reversed after treatment discontinuation.